Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense knockdown of PKC-alpha using LNA-oligos.

Jens Bo Hansen1, Majken Westergaard, Charlotte Albaek Thrue

  • 1Cureon A/S, Copenhagen, Denmark. bh@cureon.com

Nucleosides, Nucleotides & Nucleic Acids
|October 21, 2003
PubMed
Summary

Locked Nucleic Acid (LNA) modifications enhance the antisense properties of ISIS 3521, a cancer drug candidate. Shorter LNA-modified oligonucleotides retain significant antisense potential, offering a promising therapeutic approach.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides.

Nucleic acid therapeutics·2022
Same author

A simple, safe and sensitive method for SARS-CoV-2 inactivation and RNA extraction for RT-qPCR.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2021
Same author

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.

Frontiers in immunology·2021
Same author

Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same author

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

Leukemia·2018
Same author

Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells.

The Journal of biological chemistry·2018

Area of Science:

  • Oligonucleotide therapeutics
  • Molecular biology
  • Cancer research

Background:

  • ISIS 3521 is a 20-mer phosphorothioate antisense oligonucleotide targeting human protein kinase C-alpha (PKC-alpha) mRNA.
  • PKC-alpha is implicated in various cancers, making its mRNA a target for therapeutic intervention.
  • Locked Nucleic Acid (LNA) is a modified nucleic acid with enhanced binding affinity and stability.

Purpose of the Study:

  • To compare the antisense properties of full-length and truncated Locked Nucleic Acid (LNA) modifications of ISIS 3521.
  • To evaluate the impact of LNA modifications on the efficacy of antisense oligonucleotides.
  • To assess the potential for shorter LNA-modified oligonucleotides in therapeutic applications.

Main Methods:

  • Antisense properties were assessed using a cellular assay.

Related Experiment Videos

  • ISIS 3521, a 20-mer phosphorothioate targeting PKC-alpha mRNA, was modified with full-length and 4-nucleotide truncated LNA.
  • The modified oligonucleotides were tested for their ability to inhibit PKC-alpha mRNA expression.

    • Main Results:

    • Locked Nucleic Acid (LNA) modifications were found to potentiate the antisense activity of ISIS 3521.
    • Oligonucleotides incorporating LNA modifications retained significant antisense potential even when truncated by 4 nucleotides.
    • This suggests that LNA can enhance the efficacy of shorter antisense sequences.

    Conclusions:

    • LNA modifications represent a promising strategy for enhancing the potency of antisense oligonucleotides like ISIS 3521.
    • Shorter LNA-modified oligonucleotides maintain substantial antisense potential, potentially leading to more efficient and targeted cancer therapies.
    • These findings support the further development of LNA-modified antisense therapies for clinical applications.